PNCK抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human cerebella tissue lysate, Primary antibody: P06883(PNCK Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 minutes    

  
  

PNCK (Pregnancy Upregulated Nonubiquitous CaM Kinase), also known as CaMKIINα or CAMK1D, is a calcium/calmodulin-dependent serine/threonine kinase identified for its upregulated expression during pregnancy. First characterized in the late 1990s, PNCK belongs to the CaMK family and shares structural homology with other CaMK members, including a catalytic domain and regulatory regions responsive to calcium signaling. Unlike ubiquitous CaMK isoforms, PNCK exhibits tissue-specific expression, notably in reproductive organs, placenta, and certain cancers. Its function is linked to cell cycle regulation, apoptosis, and cellular stress responses, though its precise mechanisms remain under investigation.

Research highlights PNCK's dual role in physiological and pathological contexts. During pregnancy, it may contribute to placental development and maternal-fetal signaling. Conversely, aberrant PNCK expression correlates with tumor progression in breast, ovarian, and renal cancers, where it potentially modulates chemoresistance and metastasis. Antibodies against PNCK have become essential tools for detecting its expression and localization in tissues or cell lines via techniques like Western blot, immunohistochemistry, and immunofluorescence. These reagents aid in exploring PNCK's diagnostic or therapeutic potential, particularly in oncology. Commercial PNCK antibodies are typically validated for specificity across human, mouse, and rat homologs, supporting cross-species studies. Ongoing research seeks to clarify its signaling networks and clinical relevance.